/PRNewswire/ Alar Pharmaceuticals Inc. (Alar, TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs).
Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid
Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid dependence. TAICHUNG, Taiwan, Jan. 13, 2022 /PRNewswire/ Alar Pharmaceuticals Inc. (Alar, TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs) for central nervous system disorders, announces the completion and positive results.